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Results
Regimen simpli cation  cation  • Improves quality of life - [1] [2] [3] Increases long-term adherence - [1] [2] [3] Reduces virologic failure (VF) - [1] [2] [3] Reduces long-term toxicities - [1] [2] [3] RPV/FTC/TDF is a well-tolerated, once daily single-tablet regimen -(STR) treatment option 4, 5 This is the  rst study to evaluate the safety and ef  rst study to evaluate the safety and ef   rst study to evaluate the safety and ef rst study to evaluate the safety and ef cacy of switching  cacy of switching  • from ritonavir-boosted protease inhibitor (PI+RTV) based HAART to a simpli ed regimen of the STR RPV/FTC/TDF in virologically  ed regimen of the STR RPV/FTC/TDF in virologically  suppressed patients Resistance development was infrequent (<1% RPV/FTC/TDF treated subjects) Resistance development was infrequent (<1% RPV/FTC/TDF treated subjects)
Switching to RPV/FTC/TDF resulted in improvement in fasting lipids, including Switching to RPV/FTC/TDF resulted in improvement in fasting lipids, including TC, LDL, TGs, and TC:HDL ratio at Week 24 and maintained through Week 48 TC, LDL, TGs, and TC:HDL ratio at Week 24 and maintained through Week 48
In vitro In vitro RPV and RTV inhibit OCT2 and MATE1, renal transporters for creatinine RPV and RTV inhibit OCT2 and MATE1, renal transporters for creatinine tubular secretion, respectively. tubular secretion, respectively. 1,2 1,2 RPV/FTC/TDF-treated subjects with pre-existing K103N had a high response rate RPV/FTC/TDF-treated subjects with pre-existing K103N had a high response rate 1  0  0  2  1  0  0  2  1  0  0  2  1  0  0  2  1  0  0  2  1  0  0  2  1  0  0  2  1  0  0 Results:CD4 and Virology Outcomes  Mean CD4 count changes from baseline to week 48  Median CD4 change was significant comparing ATV/RAL to Control (p=0.010) and comparing ATV/rtv/RAL to Control (p=0.018).
 Virology  Through week 48, there were n=3 observed virologic failures (>200 c/mL on 2 consecutive tests), all on ATV/RAL.
 These three had self-reported 100% adherence at one or both study visits associated with viremia.
 However, study staff documented a history of difficulty adhering to the regimen  Resistance testing was attempted in all subjects with confirmed virologic failure; results either did not detect resistance or were non-amplifiable. Results: Adverse Events and Safety  Adverse events (AE) were categorized by body system. Most AEs were transient. In this pilot, only differences of >5 events within a category between arms is summarized below.
 Frequency (n) of AEs by category regardless of assessment of causation: Mean change in limb fat: There were greater rises in limb fat in the PI monotherapy arm compared to the control arm for four of the five trials. This difference was statistically significant in two of the trials when analysed individually (p<0.05 for the Monark trial, p=0.011 for the MONOI trial). However in the KRETA trial, there was a non-significant trend for greater rises in limb fat in the control arm at Week 48. In the meta-analysis, there was a significantly greater rise in limb fat for the PI monotherapy arms compared to the triple therapy control arms (p=0.024).
Mean change from baseline to Week 48 in limb fat, by treatment arm _______________________________________________________________________________________________ Clinical trial
Mean change from baseline in limb fat:
Mean change in trunk fat: there were no significant differences between the treatment arms, either for the trials analysed individually, or in the meta-analysis. 
Lipoatrophy: There were significantly fewer patients with lipoatrophy in the PI monotherapy arms compared to the control arms for three of the trials analysed individually (p<0.05, chi-square tests), and for the overall meta-analysis (p=0.03). Long-term antiretroviral treatment has led to two unexpected changes in fat distributionlipoatrophy and lipohypertrophy -which can affect patient quality of life, stigma and cardiovascular morbidity.
Changes in body composition are accurately measured using DEXA (Dual-energy X-ray absorptiometry) scanning.
Switching from triple combination treatment to protease inhibitor (PI) monotherapy may prevent or reverse adverse events related to long-term nucleoside analogues.
Lipoatrophy is associated with long-term use of thymidine analogues (zidovudine, stavudine).
The aim of this meta-analysis was to collect all data from randomized clinical trials of protease inhibitor monotherapy versus triple combination therapy, and compare measures of lipodystrophy between the two treatment strategies. 
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Six randomised trials of PI monotherapy versus triple therapy had data available in changes in either limb or trunk fat, using DEXA scanning.
In the meta-analysis, the risk of lipoatrophy was significantly lower for patients taking PI monotherapy, compared to triple therapy.
There was no significant difference between the arms for lipohypertrophy.
However, several of the trials included zidovudine in the control arm, which carries a higher risk of lipoatrophy than the more widely used alternatives: tenofovir and abacavir.
A detailed MEDLINE search was conducted to identify randomised clinical trials of triple combination treatment versus PI monotherapy. Summary results from analysis of changes in body composition (DEXA analysis) were collected: the mean change in limb fat and trunk fat from baseline to Week 48 (or 96), and the percentage of patients with lipoatrophy (20% reduction from baseline in limb fat) or lipohypertrophy (20% rise from baseline in trunk fat).
The same methods were then used to compare three other measures of lipodystrophy, all measured by DEXA: (i) the mean change from baseline to Week 48 in trunk fat (ii) the number of patients with a 20% decrease from baseline to Week 48 in limb fat (lipoatrophy), and (iii) the number of patients with a 20% increase from baseline to Week 48 in trunk fat (lipohypertrophy).
The primary endpoint for this analysis was the mean change in limb fat from baseline to Week 48 (or 96) -this continuous measure of change in limb fat was predicted to have the highest statistical power to detect differences between treatment arms. This measure was compared between the PI monotherapy arm and triple combination therapy arm across the trials using inverse variance weighting. We used estimates of variability (standard deviation of the mean change from baseline) from the available trials for the meta-analysis.
A retrospective chart review was undertaken with informed consent for patients seen at the Vancouver Infectious Diseases Centre.
We identified all patients in whom KVX was prescribed (following appropriate HLA-B5701 screening and CCR5 tropism testing) with either raltegravir (RGV) or maraviroc (MVC) as initial therapy or as a switch from another regimen.
Follow-up was according to clinical standards at months 1, 3 and then quarterly.
The key endpoints were the achievement or maintenance of virologic suppression (HIV RNA < 50 copies/mL), changes in the CD4 cell count on KVX-based therapy as well as the evaluation of drug-associated toxicity, adherence, resistance and regimen modifications.
As the long-term efficacy of antiretroviral therapy regimens is confirmed, there is a need to identify additional combinations that exhibit long-term safety and potency, while also favoring simplicity of administration.
With this in mind, we undertook a review of the use of abacavir/lamivudine (Kivexa, KVX)-based regimens using integrase or CCR5 inhibitors as the third agent. 
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OBJECTIVE Figure 1. Antiretroviral medications used with Kivexa
In patients treated with KVX in combination with RGV or MVC, virologic suppression was achieved or maintained in 89%of the patients. Immunologic responses (CD4 cell counts) were generally improved and there were no significant drugrelated toxicities.
KVX-based regimens are safe and effective alternatives to more commonly used regimens in clinical practice, and offer the benefit of good long-term tolerability and little or no need to enhance follow-up for laboratory-based abnormalities.
Consideration should be given to non-NNRTI and non-PIbased regimens to address issues of toxicity and simplification without apparent loss of efficacy. Median adherence to KVX-based therapy exceeded 88%.
Virologic failure (confirmed HIV RNA> 50 copies/mL) occurred in 4 cases (11%) all due to incomplete adherence.
Virologic failure with the development of M184V mutation was observed in 3/4 non-suppressed patients.
Loss of CCR5 tropism was observed in one case; however, the subject was not taking MVC.
RGV resistance (N155H) was observed in one nonsuppressed patient taking RGV.
There were no treatment discontinuations for toxicity and no medication-associated serious adverse events. Switches to these regimens included replacement of the third agent with MVC or RGV (n=13), replacement of the NRTI backbone with KVX (n=13) or both (n=9). • Etravirine, a second generation NNRTI, has been shown to have rates of CNS side e ects similar to placebo in it's registrational trial (Duet), has a favorable lipid pro le and has shown robust antiretroviral activity. These, and other prop erties, make it an excellent candidate as a replacement for efavirenz or a boosted PI in patients with side e ects on their initial regimen.
MAPLE LEAF MEDICAL CLINIC
o Nguyen et al, reported that patients on long term efavirenz did not prefer a switch to etravirine.
-In this small study (n=58), patients who did not complain of CNS side e ects were switched.
o In our study, 27/31 patients switching from efavirenz had complaints of CNS symptoms -in all but 1, CNS symptoms were reported to have improved or resolved.
o Supporting the results of our study, Nelson et al showed, in a randomized trial of efavirenz compared to etravirine in treatment naïve HIV infected individuals, that the rate of CNS side e ects was signi cantly lower in the etravirine group.
• Both boosted PIs and efavirenz have increase lipid levels. In our study, we were able to show a decrease of TC, LDL and triglycerides and no change in HDL o In the switch study by Nguyen mentioned above, there was an improvement of lipid pro les in patients after switching to etravirine. o with the availability of new single tablet regimens that include new well-tolerated medications such as rilpivirine/tenofovir/emtribiticine will provide more choices for simpli cation and side e ect management
• Because HIV-infected individuals are being treated earlier in the course of their chronic disease management, the duration of exposure to medications is longer. Current antiretrovirals (ARVs) may have side e ects that limit their long term use in many patients.
• 2 common sets of side effects are: Neuropsychiatric symptoms associated with efavirenz Dyslipidemia associated with both PI and efavirenz use
• Newer ARVs such as etravirine and raltegravir have comparatively less reported side e ects of these types in clinic trials
• Switching patients to etravirine is an option to reduce the long-term side e ect burden of ARVs
• Etravirine has a number of properties that make it a good choice as part of a simplified, well tolerated regimen: 1) Potent NNRTI 1.99 log decrease in VL in phase I/ll 7 day mono-therapy studyGrundev et al 2) Good lipid pro le 3) Good side e ect pro le i. This work was supported by Boehringer Ingelheim España S.A. The authors were fully responsible for all content and editorial decisions, and were involved at all stages of poster development. The authors received no compensation related to the development of the poster. A significant increase of 7 % was observed in total cholesterol after 96 weeks. No significant differences were observed in triglycerides changes during follow up.
RESULTS
CHANGES IN TRIGLYCERIDES AND TOTAL CHOLESTEROL
No significant differences were observed in ALT or AST changes during follow up.
A significant increase of 10% and 14% was observed in LDLc and HDLc, and a significant decrease in TC/HDL ratio (-5%, p=0.04) after 96 weeks, respectively.
After 48 weeks, VL was < 40 c/mL in 82% (ITT) and 94% (OT), and in 94% (OT) after 96 weeks. Median CD4 count at baseline, 48 weeks and 96 weeks was 570, 598 and 673, respectively. • Adherence is important to the long-term success of antiretroviral regimens. [1] [2] [3] Once-daily regimens have been shown to improve regimen adherence, leading to better safety and efficacy. 4 • Nevirapine (NVP) has been shown to have minimal untoward effects on serum lipids and therefore should be considered as the NNRTI of choice in patients who have an elevated cardiovascular risk profile.
• NVP plus tenofovir/ r/ r emtricitabine (TDF/FTC) has been shown to have noninferior safety and efficacy compared with atazanavir/ r/ r ritonavir plus TDF/FTC as well as a less atherogenic lipid profile. 5 • Recently, NVP extended-release (NVP XR; 400 mg) was approved for oncedaily dosing, based on studies that demonstrated comparable efficacy to twice-daily regimens of NVP immediate-release (NVP IR; 200 mg twice daily) in treatment-naïve individuals. 6 • The present report describes the efficacy and safety of switching patients who are virologically controlled on NVP IR 200 mg twice daily to NVP XR 400 mg once daily.
• TRANxITION was an open-label, randomized, parallel-group study to assess the efficacy and safety of switching HIV-V-V 1-infected patients who were established on a NVP IR-based regimen to a NVP XR-based regimen.
• Upon meeting the screening criteria, patients were randomized 2:1 to receive either NVP XR 400 mg once daily or to continue receiving NVP IR 200 mg twice daily. Baseline randomization was stratified by background NRTI therapy, which patients maintained throughout the trial. 
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• The 400 mg XR formulation was generally well tolerated, safe, and effective up to 144 weeks, both in patients who were randomized to switch from IR to XR in the initial phase (completing at least 144 weeks on XR) as well as in those who switched to XR after 48 weeks on IR (completing at least 96 weeks on XR.
-Efficacy
• At week 48, 96% of patients in the IRpost48XR and 97% of those in the XRpost48XR groups had undetectable VL (VL <50 copies/mL).
• At week 144, 95% of patients in the IRpost48XR and 95% of patients in the XRpost48XR groups had undetctable VL (VL <50 copies/mL).
• At the last available observation for all patients, 93.8% had VL <50 copies/mL.
-Safety
• Post 48 week data showed that the frequencies of various AE categories were similar to but slightly lower for NVP IR patients who switched to NVP XR after week 48 compared with patients who took NVP XR from the beginning of the study.
• The most frequent AEs post week 48 were consistent with those reported over the 144-week duration of the trial, with the majority of reported AEs being of either mild or moderate intensity.
• Less than 3% of patients discontinued treatment due to an AE over the 144 weeks of the trial. • Statistics -The primary endpoint and the corresponding 95% confidence interval (CI) were analyzed using the TLOVR algorithm by the Cochran's statistical test. A noninferiority test for the primary endpoint (12% margin) was based on a 2-sided 95% CI for any difference in the virologic responses of the 2 treatment arms (NVP XR vs NVP IR). All safety data were examined by descriptive statistical methods.
Conclusions
Patient disposition
• Patient disposition is presented in Figure 1 . After enrollment, 54 patients were excluded primarily due to failure to meet trial eligibility criteria. Of the 499 patients enrolled, 445 were randomized and 443 were treated (148, NVP IR; 295, NVP XR). After week 48, 130/143 patients remaining in the NVP IR arm exercised their option to switch to the NVP XR formulation, whereas 13 patients continued on NVP IR.
Results
Patient baseline characteristics
• No significant differences were observed in the baseline characteristics between patients in any of the treatment groups ( Table 1) .
Efficacy results
• Primary endpoint -week 24 -As measured by the primary endpoint, NVP XR was noninferior to NVP IR, with 93.6% of patients in the NVP XR arm and 92.6% of patients in the NVP IR arm achieving SVR at week 24, with an adjusted difference of 1.0% (95% CI, -4.3, 6.0), using the TLOVR algorithm and Cochran statistics, and with adjustment for all 3 background treatments. -No significant difference was seen in median change from baseline to week 24 in CD4+ cell counts (NVP IR 32.5 cells/mm 3 vs NVP XR 39.8 cells/mm 3 ) between the 2 treatment groups.
• Post week 48 eff ff f icacy analysis -A total of 130 IR patients switched to NVP XR after week 48. At each visit after week 48, more than 90% patients observed VL <50 copies/mL. -At week 48, 96.2% (95% CI, 92.8, 99.5) of remaining patients in the NVP IR/NVP XR group observed VL <50 copies/mL ( Table 2 ). In patients continuing on the NVP XR treatment, the proportion was 97. 7. 71% (95% CI, 95.1, 99.1). -At week 144, 95.0% (95% CI, 91.2, 98.9) of remaining patients in the NVP IR/NVP XR group had an observed VL <50 copies/mL. -In patients continuing on the NVP XR treatment, the proportion at week 144 was 95.2% (95% CI, 92.6, 97. 7. 78 ). -At the last available observation for all patients, 93.8% had VL <50 copies/mL. -For 276 NVP XR patients remaining on NVP XR after week 48, similar rates were observed at each visit. -Using 400 copies/mL as the lower limit for response rate, even higher numbers (100% for all treatment groups at week 144) were observed across different treatment groups. No significant correlations were found between reason for changing treatment and age, gender, race, nationality and level of education Simplification was significantly the main reason of treatment change in both employed and unemployed patients (p<0.01)
• Treatment simplification was the most prevalent reason for a change of treatment.
• Even in advanced lines of treatment. This is so probably because of the advent of ARV drugs that are more potent and effective, with less toxicity and more convenient
• Treatment simplification was significantly the first cause of treatment change in those patients who are currently working or seeking for a job. This highlights the need for simpler regimens that can adapt to an active life.
